Oncogenex Pharmaceuticals Inc., of Bothell, Wash., executed an initial agreement with Teva Pharmaceutical Industries Ltd., of Jerusalem, to regain rights to custirsen, an investigational compound being evaluated in phase III development as a treatment for prostate and lung cancers.